STUDresearch · Peptide
Wolverine stack
Also known as
Wolverine blend · BPC-157 + TB-500 · BPC/TB stack · BPC TB stack · wolverine peptide stack · healing stack (BPC+TB) · Wolverine peptide blend · BPC-157/TB-500 combo
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Lots of talk
Mixed
SubQ pair / fixed-ratio blend
Healing stacks (named blends)
Mixed — BPC near the injury, TB as whole-body mobility. That’s the forum split.
What people say
Wolverine is a community nickname for combining BPC-157 with TB-500, either separately or in a fixed-ratio blend. It is not one molecule or a standardized approved injury treatment.
Doses people talk about
These are descriptive forum and clinic patterns, not a progression. Fixed-ratio blends cannot be converted into separate-vial schedules without exact labeled component concentrations.
How it may feel
There is no dependable shared feel curve. One same-author log was unchanged at week 1 and stopped at week 2 after worse neuropathy symptoms; another reported improvement around week 3, a brief recurrence with harder training, a one-day eye-irritation event of uncertain relation, then a quieter final month and no other benefits.
Separate-vial community patternBPC-157 ~250–500 mcg/day SubQ + TB-500 ~2–2.5 mg twice weekly
Preserved notes describe a 4–6-week TB-500 loading period beside daily BPC-157, then less-frequent TB-500 use.
Same-author stopped course250 mcg BPC-157 on day 1, then 500 mcg/day + 1 mg TB-500 twice weekly SubQ
Week 1 brought no change; week 2 brought worse neuropathy symptoms and the author stopped, later confirming no further change.
Equal-ratio daily report500 mcg BPC-157 + 500 mcg TB-500 once daily in the evening
A two-month blend report placed pain-free training around week 3, a brief recurrence after harder training, no pain during the last month, no other benefits and one uncertain one-day eye-irritation episode followed by a brief pause/restart.
Wider BPC-157 charts~200–500 mcg BPC-157 once or twice daily
Some clinic pages discuss daily totals toward ~0.5–1 mg; no combo dose-ranging trial validates the range.
Wider TB-500 charts~2–5 mg TB-500 twice weekly
Community loading charts use this intermittent pattern, not a daily BPC-style schedule.
Half-life & effect duration
- Half-life in the body
- BPC-157 · IV / muscle · rats / dogsAbout 5 to under 30 minutes
- TB-500 · community estimatesAbout 2 hours or 100+ minutes
- Felt duration people report
- Positive accountImprovement around week 3
- Other accountsNo early change, or worsening nerve symptoms by week 2
- Follow-upsSymptoms sometimes returned with increased load
Cycles people discuss
Community patterns usually pair daily BPC-157 with intermittent TB-500 over roughly 4–8 weeks, sometimes longer around chronic or postoperative problems. Those are observed templates, not combo trial schedules.
Timing
Observed schedules differ: one stopped-course report used daily BPC-157 plus TB-500 twice weekly, while the positive equal-ratio blend report used both once daily in the evening. Preserved community charts likewise pair daily BPC-157 with intermittent TB-500; none is a validated combination schedule.
Stacks
BPC-157 plus TB-500 is the core pair; GHK-Cu or KPV additions create different, more confounded stacks. PT, sleep, nutrition and load management are frequent non-drug co-drivers.
Access talk
No Wolverine vote: July 23, 2026 PCAC recommended BPC-157 and TB-500 each 8–6 (1 abstention) as separate bulk substances. The stack name is forum/clinic branding.
Labs people mention
Inflammation labs: hs-CRP and sometimes ESR are what 2026 Wolverine-monitoring posts name.
Watch for
Source / purity risk: Gray-market under-fill, over-fill, wrong fragment, or mislabel — blend vials are harder to audit than single-API vials.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
Prototype BPC-157 had an elimination half-life from about 5 minutes to under 30 minutes in rat and dog IV/IM studies.
The open ADME study measured species- and route-specific parent-peptide PK; it did not study the Wolverine combination.
Animal IV/IM results do not establish human or SubQ gray-market-product PK and do not measure a tissue-repair duration.
- Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs (opens in a new tab)Read the full open article, including abstract, administration methods and PK tables: prototype BPC-157 had elimination half-life under 30 minutes after IV or IM administration in rats and beagle dogs.Animal IV/IM prototype-drug study; it does not measure the SubQ gray-market products used in Wolverine reports or prove a human tissue-repair duration.
Half-life in the body
No human TB-500 fragment elimination half-life is established.
FDA found no clinical studies or human exposure data for TB-500 by any route, so full-length thymosin beta-4 numbers cannot supply a fragment half-life.
A regulatory absence review is not a PK experiment; marketed product identity and fragment definitions can also vary.
- FDA briefing document for TB-500-related bulk drug substances (opens in a new tab)Read the FDA clinical and safety sections: no clinical studies or human exposure data for TB-500 by any route were identified, and published blended BPC-157/TB-500 reports lacked safety assessments.Regulatory evidence review, not a pharmacokinetic experiment; its search date and nominated substance definitions bound the conclusion.
Felt duration people report
Actual reports diverge from no early change to improvement around week 3 or symptom worsening by week 2; no stable combo feel window emerges.
One same-author course stopped after worsening neuropathy symptoms at week 2, while an equal-ratio daily blend report described improvement, a load-related recurrence, one uncertain one-day eye-irritation event, and later quiet symptoms with no other benefits.
Unverified products, different component ratios, baseline conditions, changing training loads, no controls and subjective endpoints.
- Real time Wolverine stack experience (opens in a new tab)Read the full post and same-author updates: day 2 BPC-157 rose to 500 mcg daily while TB-500 stayed 1 mg twice weekly; week 1 had no change or side effects; week 2 brought worse small-fiber-neuropathy burning and autonomic symptoms, followed by stopping; a later reply confirmed no further change after stopping.Single self-selected report with unverified products, multiple baseline conditions, no control and author-attributed causality.
- Taking the Wolverine stack and its amazing (opens in a new tab)Read the post and same-author follow-ups: 500 mcg BPC-157 plus 500 mcg TB-500 once daily in the evening for two months; pain-free training at about three weeks, pain recurrence a week later after harder training, no pain during the last month, and no other reported benefits. The author also reported one day of right-eye irritation in week 2, paused for three days, restarted without complications and was unsure it was related.Single unverified equal-ratio blend report with changing training load, no imaging, no control, no proof that either ingredient caused the trajectory, and uncertain attribution of the eye irritation.
What people say
- Soft-tissue bounce-back: Users report faster recovery from strains, tweaks, and training niggles vs rest alone — heavily confounded by deload and PT. forum
- Tendon / joint “noise”: Common logs of less daily tendon or joint complaint over multi-week blocks (often cited around weeks 2–4+). forum
- Local + systemic coverage: Stack sold as covering both the injury site (BPC) and broader repair environment (TB). forum
- Flexibility / ROM feel: TB side of the stack often gets credit for looser connective-tissue feel or improved range. forum
- Training continuity: Anecdotes of staying in the gym with nagging issues while managing load — not a substitute for diagnosis. anecdote
- Post-op / post-procedure interest: Clinics and forums discuss the pair around surgical recovery windows; human MSK trial evidence remains thin. forum
- Synergy narrative: “BPC alone for local, TB alone for systemic, both for stubborn connective tissue” is the standard forum line. forum
- Stack halo: Wins frequently co-credited with sleep, protein, load management, and physical therapy. forum
- Women vs men: Same as the two peptides — not a loud sex-split stack. Injury and mg/mcg, not “women’s Wolverine.” forum
- Animal backdrop (components, not combo proof): BPC-157 and Tβ4/fragment literature include wound, tendon, and angiogenesis models — bro culture extrapolates to the stack name. animal
Doses people talk about
- Separate-vial classic (most repeated honest pattern): BPC-157 ~250–500 mcg/day subq (sometimes split ~250 mcg 2×/day) plus TB-500 ~2–2.5 mg 2×/week for ~4–6 weeks load, then ~2–2.5 mg 1×/week maintain. Shorthand: ~0.25–0.5 mg BPC daily / ~2–2.5 mg TB 2×/wk → weekly. forum
- Wider BPC talk: ~200–500 mcg 1–2×/day; some clinic pages discuss up toward ~0.5–1 mg/day BPC — still not a trial standard. forum
- Wider TB talk: Load ~2–5 mg 2×/week in more aggressive charts; maintenance often ~2–2.5 mg weekly or less often. forum
- Pre-mixed “equal daily” vials: Some 5/5, 10/10, or 5/10 mg BPC/TB products get dosed as one daily combined shot. Example forum/clinic-adjacent talk for a 10/10 style mix: about ~0.5 mg BPC + ~0.5 mg TB in the same daily draw — that is not the same exposure as multi-mg TB 2×/week. forum
- How to write blend amounts: Prefer BPC/TB pairs (e.g. 0.5/0.5 mg or 0.25/0.25 mg per day for equal-ratio daily culture) — not a single “total peptide mg” without naming each. forum
- Local vs systemic pin talk: BPC often near (not into) the complaint site; TB usually abdomen/thigh as “systemic.” Pre-mixes force both from one site. forum
- Oral BPC detour: Oral/sublingual BPC (~250–500 mcg) shows up for gut/convenience; TB-500 stays inject-only in almost all stack talk. forum
- vs GLOW/KLOW: Those pre-blends pin GHK (± KPV) every day and usually under-dose TB vs classic Wolverine TB loading — different recipes, not “same stack with extra names.” forum
- Nasal stack camp: Combo sprays exist; careful 2026 threads still say that is not the Wolverine people mean when they compare 250–500 mcg BPC + 2–2.5 mg TB. forum
- Same syringe vs separate: Supervised writeups often keep peptides separate unless the product is a labeled pre-blend. forum
- Unit-label caution: Forum screenshots mix syringe-unit shorthand across different vial concentrations and combined-versus-per-peptide labels. Those numbers are not portable without the exact product label. forum
- Framing: Community/clinic-marketing ranges only — not medical advice. “Wolverine” = BPC-157 + TB-500, not one drug. forum
How it may feel
- Days 1–7: One same-author log reported no changes or side effects at week 1 on 500 mcg BPC-157 daily plus 1 mg TB-500 twice weekly; other accounts are similarly quiet early. forumanecdote
- Weeks 1–2: Early anti-inflammatory / stiffness anecdotes (often pinned on TB); injury-site warmth or “healing noise” sometimes mentioned. forum
- Weeks 2–4: Reports diverge: one log stopped at week 2 after worsening neuropathy symptoms, while another daily equal-ratio report described pain-free training around week 3, recurrence a week later after harder training, and a separate one-day eye-irritation episode followed by a pause/restart without recurrence; that author was unsure the eye issue was related. forumanecdote
- Weeks 4–6: Typical end of TB loading talk and decision to maintain, taper BPC, or stop. forum
- Weeks 4–8: Standard full acute-injury block length in vendor and forum protocols. forum
- Weeks 8–12: Chronic or post-op talk sometimes extends; reassess function before more product. forum
- No change ~4 weeks: Forums push diagnosis, imaging, load, sleep, and form before “more peptide” or stack creep. forum
- Post-cycle: Minor issues may “stick”; hard structural injuries often return complaints when load ramps — tissue remodeling talk vs permanent fix. anecdote
- Two feel curves in one log: BPC days are usually quiet; TB’s first multi-mg shot is the one more likely to feel tired/flu-ish. Week 2–4 is still the shared “is the tendon quieter?” checkpoint. forum
- Bloodwork people mention: hs-CRP / ESR and CMP show up in 2026 “Wolverine labs” roundups. Neither peptide is treated as a hormone drug on standard panels. forum
Around the dose
- Clock: BPC is daily (often AM or split); TB is a few times per week. They are not the same schedule. forum
- Training: Post-session or away from the heavy set is common. Pinning immediately before a max-effort lift isn’t a ritual. forum
- Local vs anywhere: BPC near the complaint; TB “anywhere SubQ” is the usual mental model. forum
- Habits: PT, sleep, and load management are the pairing people mention when Wolverine logs look good. forum
- After-dose context: Logs that improve usually also mention tolerable movement, PT or load management; complete rest and aggressive return to training both complicate interpretation. forum
- Belly vs site: Separate vials let BPC sit near the complaint and TB go abdomen. One blend shot cannot do both jobs. forum
Cycles people discuss
- Acute injury block: ~4–8 weeks of BPC+TB together is the most common community template. forum
- TB load then maintain: Load ~4–6 weeks, then weekly/biweekly maintain or stop; BPC often continues daily through the block. forum
- Example 8-week structure: Weeks 1–4 daily BPC + TB 2×/week → weeks 5–8 daily or reduced BPC + TB 1×/week → reassess. forum
- Extended chronic / post-op talk: ~8–12 weeks appears; function should drive continuation, not only vial count. forum
- Time off: ~4 weeks off after ~8 on is common talk; some stop when symptoms quiet without a fixed calendar. forum
Timing
- BPC community half-life talk: Forums also cite short hours-scale clearance and “effects outlast blood levels” remodeling stories. forum
- TB-500 plasma talk: Often described in hours (e.g. ~2 hours or ~100+ minutes SC narrative in secondary sources) — not multi-day depot PK like some GH peptides. forum
- Why TB is still weekly culture: Bro logic is multi-mg loading + longer tissue/actin effects, not long plasma half-life; plasma vs tissue-effect distinction is constantly blurred in marketing. forum
- Why both schedules coexist: Short-lived daily BPC + intermittent multi-mg TB is the design feature of the dual stack. forum
- Timing flexibility: Unlike GH secretagogues, empty-stomach circadian rules are usually not central; consistency and site choice matter more in logs. forum
- Same-day co-admin: BPC can be daily morning/evening; TB on designated load/maintain days — need not be the same clock time. forum
- Downstream remodeling: Users separate “still in blood” from “tissue still remodeling for weeks.” anecdote
- Identity PK caution: Half-life claims for “TB-500” often import full Tβ4 literature — treat numbers as soft. forum
- BPC plasma PK (animal data): Prototype BPC-157 elimination half-life reported under ~30 minutes in rat/dog PK work after IV/IM — supports daily or multi-daily community dosing culture. animal
More on what it is
- Name culture: “Wolverine stack” on X/Reddit almost always means BPC + TB, not a single drug. Still the injury default in 2026 threads. forum
- What it is: Community nickname for stacking BPC-157 + TB-500 (or a pre-mixed “Wolverine blend” vial) for injury, tendon, and soft-tissue recovery talk. forum
- Not one drug: Two separate research peptides — not an FDA-approved combo product, not a single molecule, not a standardized pharmaceutical. forum
- Why “Wolverine”: Comic-style rapid-healing meme that stuck across forums, clinics, podcasts, and vendor marketing. forum
- Division of labor (bro model): BPC framed as local repair / angiogenesis / “build the pipes”; TB-500 framed as actin / cell-migration / whole-body mobilizer. forum
- vs GLOW: GLOW = Wolverine core + GHK-Cu (skin/collagen/ECM “glow” marketing). forum
- vs KLOW: KLOW = GLOW-style base + KPV (extra inflammation / gut-skin marketing). forum
- 2026 compounding-vote mix-up: FDA PCAC voted on BPC-157 and TB-500 separately (each 8–6, 1 abstention, July 23, 2026). It did not vote on a “Wolverine” drug or a fixed combo. “FDA approved Wolverine” is a forum error. trialforum
- Two unapproved peptides, one nickname: Even if both later land on a 503A bulks list, that is compounding eligibility talk — not proof the stack heals tendons and not a license for RUO 10/10 blend vials. forumtrial
- Nasal combo sprays: 2026 shops sell BPC+TB nose sprays. Size-talk calls BPC (~1,400 Da) borderline-poor and TB “too big” (tables often use full Tβ4 ~5 kDa; the fragment is smaller). Honest threads keep Wolverine as two pins, not a spray. forum
- TB identity caveat: Marketed “TB-500” is often discussed as a thymosin β-4 fragment (analytical ID sometimes Ac-LKKTETQ / residues 17–23), not full-length 43-aa Tβ4 — labels and research citations get mixed. trial
- Evidence honesty: Each peptide has animal and sparse human discussion of its own; robust head-to-head combo RCTs for MSK injury in humans are essentially absent — stack talk is protocol culture, not proven superiority. trial
- Research only: Named stack chatter ≠ medical protocol or prescription. forum
Stacks
- Core only: BPC-157 + TB-500 = classic Wolverine — default dual for soft-tissue. forum
- Upgrade → GLOW: Add GHK-Cu for collagen/skin/ECM marketing on the same repair core. forum
- Further → KLOW: Add KPV (usually on a GLOW-style base) for inflammation / gut-skin narratives. forum
- GH axis: Often next to CJC-1295 (no DAC)/Ipamorelin or MK-677 for sleep/recovery lifestyle stacks — confounds outcomes. forum
- BPC-only or TB-only seasons: Some run one peptide if budget or goal is purely local vs systemic. forum
- Full Tβ4 debate: Fragment TB-500 vs full-length thymosin beta-4 products in “which healing peptide” threads. forum
- Non-drug stack: PT, mobility, deload, sleep, and nutrition almost always listed as co-drivers. forum
Access talk
- No Wolverine vote: July 23, 2026 PCAC recommended BPC-157 and TB-500 each 8–6 (1 abstention) as separate bulk substances. The stack name is forum/clinic branding. trialforum
- Not FDA-approved: Two advisory compounding recommendations ≠ approved combo product ≠ finished 503A listing. trialforum
- Blend identity: RUO 5/5 or 10/10 “Wolverine” vials, a clinic compounded pair, and two separate prescriptions (if compounding ever lands) are different products. forum
- RUO still loud: Gray-market dual vials did not become pharmacy products because a committee voted. forum
- Reviewed uses were not “the stack”: BPC was heard for ulcerative colitis; TB-500 for wound healing. Not a sports-injury combo indication. trial
Labs people mention
- Inflammation labs: hs-CRP and sometimes ESR are what 2026 Wolverine-monitoring posts name. forum
- Safety baseline: CMP/liver and a CBC get listed as “before you pin,” not as a stack scoreboard. forum
- No combo marker: There is no lab that proves the stack is working. People still judge pain/noise and training load. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
- Two maths on one syringe: People argue 10 units vs 100 units because they borrowed a BPC screenshot for a TB draw, or a blend vial with mystery water. Units only mean something after both amounts and the water are known. forum
Watch for
- Injection site: Redness, sting, itch, or bruise common with either peptide or blends. forum
- TB systemic oddities: Headache, lethargy/fatigue, or mild nausea after larger mg shots appear in side-effect writeups and logs. forum
- Source / purity risk: Gray-market under-fill, over-fill, wrong fragment, or mislabel — blend vials are harder to audit than single-API vials. forum
- Ratio lock-in: Pre-mixes force fixed BPC:TB proportions; you cannot independently raise TB load without also raising daily BPC (or vice versa). forum
- Unit-math errors: Most common practical failure mode — 5 vs 10 units, total-blend vs per-peptide mcg, and 5/5 vs 10/10 labels. forum
- Cancer / angiogenesis caution: Both peptides sit in growth/angiogenesis/cell-migration narratives; theoretical tumor-support debates are common. No definitive human trial proving the stack causes cancer, but active or recent cancer history is a frequent community and clinician red-flag discussion. forum
- Confounded results: Rest, PT, NSAID changes, and load management often drive the real outcome. forum
- Not risk-free OTC: Two research chemicals (or a compounded research blend) ≠ a safe consumer product. forum
- Legal / regulatory: Research-only labeling, compounding clinic access, and consumer gray-market status vary by jurisdiction; not FDA-approved as an injury drug combo. forum
- Infection / sterile technique: Multi-use vials and home injection carry standard contamination risk. forum
- Stack creep: Adding GHK-Cu, KPV, GH secretagogues multiplies purity, side-effect, and cost unknowns. forum
- Oral vs inject fights: Oral BPC for gut vs inject-near-site for tendons is debated; TB oral is not the stack standard. forum
- Long-term unknown: Multi-cycle yearly use lacks established long-term human safety data. forum
- “FDA approved Wolverine” mix-up: Two separate 8–6 compounding recommendations are not approval of the stack, not a standardized 5/5 or 10/10 vial, and not a purity stamp. forumtrial
- Evidence gap: Human MSK RCTs for the combo are essentially missing; animal component data ≠ proven sports-injury protocol. trial
- Anti-doping: TB-500 / thymosin β-4 derivatives and BPC-157 appear on WADA prohibited frameworks — tested athletes treat the stack as a ban risk. trial
- TB ≠ full Tβ4: Quoting full-length thymosin β-4 studies as proof for fragment products is a known category error. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.